{"id":59070,"date":"2026-03-09T12:44:55","date_gmt":"2026-03-09T04:44:55","guid":{"rendered":"https:\/\/flcube.com\/?p=59070"},"modified":"2026-03-09T12:44:56","modified_gmt":"2026-03-09T04:44:56","slug":"cf-pharmtech-wins-nmpa-approval-for-olopatadine-mometasone-combo-trial-fixed-dose-nasal-spray-targets-moderate-to-severe-allergic-rhinitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59070","title":{"rendered":"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis"},"content":{"rendered":"\n<p><strong>CF PharmTech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2652:HKG\">HKG: 2652<\/a>) announced <strong>NMPA clearance<\/strong> to initiate a <strong>clinical study<\/strong> for its <strong>fixed-dose combination<\/strong> of <strong>olopatadine<\/strong> (antihistamine) and <strong>mometasone<\/strong> (corticosteroid) for the treatment of <strong>moderate-to-severe allergic rhinitis<\/strong> in <strong>adults and adolescents aged 12 years and older<\/strong>. The <strong>single-formulation nasal spray<\/strong> addresses unmet needs in the <strong>respiratory allergy market<\/strong> by combining dual mechanisms for enhanced symptom control and improved patient adherence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Olopatadine + mometasone fixed-dose combination<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Nasal spray (single-device)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-severe allergic rhinitis<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Adults and adolescents \u226512 years<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>CF PharmTech Inc. (Wuxi, China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Class<\/th><th>Mechanism<\/th><th>Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>Olopatadine<\/strong><\/td><td>H1-antihistamine (selective, non-sedating)<\/td><td>Blocks histamine H1 receptors; mast cell stabilization<\/td><td>Rapid relief of nasal itching, sneezing, rhinorrhea<\/td><\/tr><tr><td><strong>Mometasone<\/strong><\/td><td>Intranasal corticosteroid (potent, low bioavailability)<\/td><td>Anti-inflammatory; reduces nasal mucosa inflammation<\/td><td>Sustained control of nasal congestion, overall symptom severity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Combination Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual pathway blockade:<\/strong> Antihistamine addresses immediate hypersensitivity; corticosteroid targets underlying inflammation<\/li>\n\n\n\n<li><strong>Convenience advantage:<\/strong> Single nasal device vs. separate antihistamine and steroid sprays (improved adherence)<\/li>\n\n\n\n<li><strong>Efficacy synergy:<\/strong> Fixed-dose timing optimizes pharmacodynamic coordination<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Allergic Rhinitis Burden<\/strong><\/td><td>400+ million affected in China; moderate-to-severe represents 30-40% of diagnosed patients<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Intranasal corticosteroids (fluticasone, mometasone) first-line; antihistamines adjunctive<\/td><\/tr><tr><td><strong>Combination Gap<\/strong><\/td><td>No fixed-dose antihistamine\/corticosteroid nasal sprays approved in China; patients use separate devices<\/td><\/tr><tr><td><strong>Adherence Challenge<\/strong><\/td><td>Complex multi-spray regimens reduce compliance; simplified single-device improves outcomes<\/td><\/tr><tr><td><strong>Competitive Threats<\/strong><\/td><td>Generic mometasone flooding market; olopatadine differentiation via combination patent protection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2026<\/td><td>Safety, tolerability, pharmacokinetics of combination formulation<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2028<\/td><td>Dose-ranging, efficacy vs. monotherapy components<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2028-2029<\/td><td>Non-inferiority\/superiority vs. free-combination standard of care<\/td><\/tr><tr><td><strong>NDA Filing<\/strong><\/td><td>2029-2030<\/td><td>China approval as first fixed-dose nasal spray for allergic rhinitis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for CF PharmTech&#8217;s olopatadine\/mometasone combination. Actual results may differ due to formulation challenges, competitive dynamics, and reimbursement decisions in the respiratory allergy market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900030_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030900030_c.\"><\/object><a id=\"wp-block-file--media-dc241372-fa11-47f8-8264-4d1b5ca75df8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900030_c.pdf\">2026030900030_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900030_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dc241372-fa11-47f8-8264-4d1b5ca75df8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4154,62,4641],"class_list":["post-59070","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cf-pharmtech","tag-clinical-trial-approval-initiation","tag-hkg-2652"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59070\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis\" \/>\n<meta property=\"og:description\" content=\"CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59070\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T04:44:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T04:44:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59070#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59070\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis\",\"datePublished\":\"2026-03-09T04:44:55+00:00\",\"dateModified\":\"2026-03-09T04:44:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59070\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CF PharmTech\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2652\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59070#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59070\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59070\",\"name\":\"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-09T04:44:55+00:00\",\"dateModified\":\"2026-03-09T04:44:56+00:00\",\"description\":\"CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59070#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59070\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59070#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry","description":"CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59070","og_locale":"en_US","og_type":"article","og_title":"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis","og_description":"CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.","og_url":"https:\/\/flcube.com\/?p=59070","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-09T04:44:55+00:00","article_modified_time":"2026-03-09T04:44:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59070#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59070"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis","datePublished":"2026-03-09T04:44:55+00:00","dateModified":"2026-03-09T04:44:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59070"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CF PharmTech","Clinical trial approval \/ initiation","HKG: 2652"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59070#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59070","url":"https:\/\/flcube.com\/?p=59070","name":"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-09T04:44:55+00:00","dateModified":"2026-03-09T04:44:56+00:00","description":"CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59070#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59070"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59070#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial \u2013 Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59070"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59070\/revisions"}],"predecessor-version":[{"id":59073,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59070\/revisions\/59073"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}